Lind H, Gameiro SR, Jochems C, Donahue RN, Strauss J, Gulley JM, Palena C, Schlom J (2020) Dual targeting of TGF-beta and PD-L1 via a bifunctional anti-PD-L1/TGF-betaRII agent: status of preclinical and clinical advances. J Immunother Cancer 8:e000433. https://doi.org/10.1136/jitc-2019-000433
Article PubMed PubMed Central Google Scholar
Wrzesinski SH, Wan YY, Flavell RA (2007) Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res 13:5262–5270. https://doi.org/10.1158/1078-0432.CCR-07-1157
CAS Article PubMed Google Scholar
Tzavlaki K, Moustakas A (2020) TGF-beta signaling. Biomolecules 10:487. https://doi.org/10.3390/biom10030487
CAS Article PubMed Central Google Scholar
Lin HY, Moustakas A, Knaus P, Wells RG, Henis YI, Lodish HF (1995) The soluble exoplasmic domain of the type II transforming growth factor (TGF)-beta receptor. A heterogeneously glycosylated protein with high affinity and selectivity for TGF-beta ligands. J Biol Chem 270:2747–2754. https://doi.org/10.1074/jbc.270.6.2747
CAS Article PubMed Google Scholar
Vugmeyster Y, Wilkins J, Koenig A, El Bawab S, Dussault I, Ojalvo LS, De Banerjee S, Klopp-Schulze L, Khandelwal A (2020) Selection of the recommended phase 2 dose for bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1. Clin Pharmacol Ther 108:566–574. https://doi.org/10.1002/cpt.1776
CAS Article PubMed PubMed Central Google Scholar
Vugmeyster Y, Klopp-Schulze L, Rueckert P, Khandelwal A, Speit I, Osada M, Grenga I (2020) Safety and pharmacokinetics of bintrafusp alfa with Q3W dosing: confirmation of the model-informed dose selection. ACOP 2020 Virtual Conference; November 9–13, 2020
Paz-Ares L, Kim TM, Vicente D, Felip E, Lee DH, Lee KH, Lin CC, Flor MJ, Di Nicola M, Alvarez RM, Dussault I, Helwig C, Ojalvo LS, Gulley JL, Cho BC (2020) Bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in second-line treatment of patients with NSCLC: results from an expansion cohort of a phase 1 trial. J Thorac Oncol 15:1210–1222. https://doi.org/10.1016/j.jtho.2020.03.003
CAS Article PubMed PubMed Central Google Scholar
Strauss J, Braiteh FS, Calvo E, Miguel MD, Cervantes A, Edenfield WJ, Li T, Rasschaert MA, Park-Simon T-W, Longo F, Paz-Ares LG, Spira AI, Jehl G, Dussault I, Ojalvo LS, Gulley JL, Allan SW (2021) Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: data from phase 1 and phase 2 studies. J Clin Oncol 39 (15_suppl):5509. https://doi.org/10.1200/JCO.2021.39.15_suppl.5509
Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, Lamping E, Marte JL, Donahue RN, Grenga I, Cordes L, Christensen O, Mahnke L, Helwig C, Gulley JL (2018) Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced solid tumors. Clin Cancer Res 24:1287–1295. https://doi.org/10.1158/1078-0432.CCR-17-2653
CAS Article PubMed PubMed Central Google Scholar
Yoo C, Oh DY, Choi HJ, Kudo M, Ueno M, Kondo S, Chen LT, Osada M, Helwig C, Dussault I, Ikeda M (2020) Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer. J Immunother Cancer 8:e000564. https://doi.org/10.1136/jitc-2020-000564
Article PubMed PubMed Central Google Scholar
Doi T, Fujiwara Y, Koyama T, Ikeda M, Helwig C, Watanabe M, Vugmeyster Y, Kudo M (2020) Phase I study of the bifunctional fusion protein bintrafusp alfa in Asian patients with advanced solid tumors, including a hepatocellular carcinoma safety-assessment cohort. Oncologist 25:e1292-e1302. https://doi.org/10.1634/theoncologist.2020-0249
Rolfo C, Greillier L, Veillon; R, Badin F, Ghiringhelli F, Isambert N, Paulus A, Lambrechts M, Chaudhary S, Xiaoli You X, Vugmeyster Y, Helwig C, Hiret S (2021) Bintrafusp alfa in combination with chemotherapy in patients with stage IV NSCLC: safety and pharmacokinetic results of the INTR@PID LUNG 024 study, Poster 465. Paper presented at the Society for Immunotherapy fo Cancers 37th Annual Meeting, Washington, DC; November 10–14, 2021
Gulley JL, Lacouture ME, Spira A, Verdaguer Mata H, Yoo C, Cho BC, Helwig C, Halady T, Valencia C, Bajars M, Strauss J, Brownell I (2021) 1689P Adverse event management during treatment with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1: treatment guidelines based on experience in clinical trials. Ann Oncol 32:S1181. https://doi.org/10.1016/j.annonc.2021.08.1661
Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, Hsu FJ, Berzofsky JA, Lawrence DP (2014) Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE 9:e90353. https://doi.org/10.1371/journal.pone.0090353
CAS Article PubMed PubMed Central Google Scholar
Kim BG, Malek E, Choi SH, Ignatz-Hoover JJ, Driscoll JJ (2021) Novel therapies emerging in oncology to target the TGF-beta pathway. J Hematol Oncol 14:55. https://doi.org/10.1186/s13045-021-01053-x
CAS Article PubMed PubMed Central Google Scholar
Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563–580. https://doi.org/10.1038/s41571-019-0218-0
CAS Article PubMed Google Scholar
Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW, Liu N, Yan CX (2017) Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol 8:730. https://doi.org/10.3389/fphar.2017.00730
CAS Article PubMed PubMed Central Google Scholar
Mitra MS, Lancaster K, Adedeji AO, Palanisamy GS, Dave RA, Zhong F, Holdren MS, Turley SJ, Liang WC, Wu Y, Meng YG, Vernes JM, Schutten MM (2020) A potent pan-TGFβ neutralizing monoclonal antibody elicits cardiovascular toxicity in mice and cynomolgus monkeys. Toxicol Sci 175:24–34. https://doi.org/10.1093/toxsci/kfaa024
CAS Article PubMed Google Scholar
Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, Cleverly AL, Desaiah D, Guba SC, Benhadji KA, Slapak CA, Lahn MM (2015) Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther 9:4479–4499. https://doi.org/10.2147/DDDT.S86621
CAS Article PubMed PubMed Central Google Scholar
Kewan T, Covut F, Ahmed R, Haddad A, Daw H (2020) Clinically significant bleeding with immune checkpoint inhibitors: a retrospective cohort study. Eur J Cancer 137:285–287. https://doi.org/10.1016/j.ejca.2020.07.005
CAS Article PubMed Google Scholar
Leighl NB, Bennouna J, Yi J, Moore N, Hambleton J, Hurwitz H (2011) Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. Br J Cancer 104:413–418. https://doi.org/10.1038/sj.bjc.6606074
CAS Article PubMed PubMed Central Google Scholar
Wang Y, Booth B, Rahman A, Kim G, Huang SM, Zineh I (2017) Toward greater insights on pharmacokinetics and exposure-response relationships for therapeutic biologics in oncology drug development. Clin Pharmacol Ther 101:582–584. https://doi.org/10.1002/cpt.628
CAS Article PubMed Google Scholar
Dai HI, Vugmeyster Y, Mangal N (2020) Characterizing exposure-response relationship for therapeutic monoclonal antibodies in immuno-oncology and beyond: challenges, perspectives, and prospects. Clin Pharmacol Ther 108:1156–1170. https://doi.org/10.1002/cpt.1953
CAS Article PubMed PubMed Central Google Scholar
ICH (2020) Introductory Guide for Standardised MedDRA Queries (SMQs) Version 23.0. https://admin.meddra.org/sites/default/files/guidance/file/SMQ_intguide_23_0_English.pdf. Accessed November 2021
Donaghy H (2016) Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs 8:659–671. https://doi.org/10.1080/19420862.2016.1156829
CAS Article PubMed PubMed Central Google Scholar
Bartram U, Molin DG, Wisse LJ, Mohamad A, Sanford LP, Doetschman T, Speer CP, Poelmann RE, Gittenberger-de Groot AC (2001) Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-beta(2)-knockout mice. Circulation 103:2745–2752. https://doi.org/10.1161/01.cir.103.22.2745
CAS Article PubMed Google Scholar
Langer JC, Henckaerts E, Orenstein J, Snoeck HW (2004) Quantitative trait analysis reveals transforming growth factor-beta2 as a positive regulator of early hematopoietic progenitor and stem cell function. J Exp Med 199:5–14. https://doi.org/10.1084/jem.20030980
CAS Article PubMed PubMed Central Google Scholar
Varricchio L, Iancu-Rubin C, Upadhyaya B, Zingariello M, Martelli F, Verachi P, Clementelli C, Denis JF, Rahman AH, Tremblay G, Mascarenhas J, Mesa RA, O’Connor-McCourt M, Migliaccio AR, Hoffman R (2021) TGF-beta1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis. JCI Insight 6:e145651. https://doi.org/10.1172/jci.insight.145651
Article PubMed PubMed Central Google Scholar
Martin CJ, Datta A, Littlefield C, Kalra A, Chapron C, Wawersik S, Dagbay KB, Brueckner CT, Nikiforov A, Danehy FT Jr, Streich FC Jr, Boston C, Simpson A, Jackson JW, Lin S, Danek N, Faucette RR, Raman P, Capili AD, Buckler A, Carven GJ, Schürpf T (2020) Selective inhibition of TGFbeta1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape. Sci Transl Med 12:eaay8456. https://doi.org/10.1126/scitranslmed.aay8456
Boilève A, Hilmi M, Smolenschi C, Ducreux M, Hollebecque A, Malka D (2021) Immunotherapy in advanced biliary tract cancers. Cancers (Basel) 13:1569. https://doi.org/10.3390/cancers13071569
Li C, Wang B, Lu D, Jin JY, Gao Y, Matsunaga K, Igawa Y, Nijem I, Lu M, Strasak A, Chernyukhin N, Girish S (2016) Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer. Cancer Chemother Pharmacol 78(3):547–558. https://doi.org/10.1007/s00280-016-3099-2
CAS Article PubMed Google Scholar
Venkatakrishnan K, Burgess C, Gupta N, Suri A, Takubo T, Zhou X, DeMuria D, Lehnert M, Takeyama K, Singhvi S, Milton A (2016) Toward optimum benefit-risk and reduced access lag for cancer drugs in Asia: a global development framework guided by clinical pharmacology principles. Clin Transl Sci 9(1):9–22. https://doi.org/10.1111/cts.12386
CAS Article PubMed PubMed Central Google Scholar
Venkatakrishnan K, Cook J (2018) Driving access to medicines with a totality of evidence mindset: an opportunity for clinical pharmacology. Clin Pharmacol Ther 103(3):373–375. https://doi.org/10.1002/cpt.926
Walsh R, Goh BC (2019) Population diversity in oncology drug responses and implications to drug development. Chin Clin Oncol 8(3):24. https://doi.org/10.21037/cco.2019.05.01
Wilkins JJ, Vugmeyster Y, Dussault I, Girard P, Khandelwal A (2019) Population pharmacokinetic analysis of bintrafusp alfa in different cancer types. Adv Ther 36(9):2414–2433. https://doi.org/10.1007/s12325-019-01018-0
CAS Article PubMed Google Scholar
Khandelwal A, Grisic AM, French J, Venkatakrishnan K (2022) Pharmacometrics golems: exposure-response models in oncology. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.2564
留言 (0)